Trends and challenges in the Pharma and Life Science Industry
Content
.jpeg)
Zanovoy has years of experience working with regulations that life sciences companies need to adhere to. Life sciences companies are subject to an increasing number of regulations from various bodies and authorities, which can make staying compliant a challenge. "With advances in genomics and biomarkers, we can provide patients with more precise treatment options. This not only improves efficacy but also significantly reduces side-effects, allowing patients to have a better treatment experience."
.jpg)
We'll ask about your current systems, the problem you are actually trying to solve, and where you are in the decision. This includes utilizing advanced communication technologies and building strong relationships with team members. In the highly competitive and rapidly evolving life sciences industry, attracting top talent is crucial to the success of project teams. US companies operating in the life sciences industry are facing intense competition on a global scale, particularly in sub-sectors such as pharmaceuticals and biotech, where multinational collaboration is increasingly common. The life sciences industry is fast-paced and constantly changing, making program management challenging.
This problem undermines the credibility of scientific findings and can impede further progress. Appian provides AI automation for the most important business processes at the world’s largest organizations. Throughout all aspects of business, across regions, life sciences organizations must comply with numerous regulations. A portfolio of disconnected processes makes execution slow and collaboration difficult, ultimately bringing forth unsatisfactory results.
03. Navigating the tooling decision precipice
Discover how organizations are navigating change and positioning themselves for long-term success. A well-structured ERM program enables organizations to anticipate obstacles and make informed decisions that support resilience and growth. Engaging in external funding efforts helps build public trust, enhances corporate reputation and supports long-term alignment with patient and societal needs.
Moreover, diverse teams drive innovation, bringing various perspectives and ideas crucial for developing groundbreaking solutions in the life sciences industry. Promoting DE&I is critical for expanding talent pools and attracting candidates from diverse backgrounds, including different ethnicities, genders, and educational experiences. By staying informed about current trends and providing benefits that resonate with employees, organisations can boost loyalty and reduce turnover, thereby minimising the need for frequent recruitment. By prioritising employee development, companies build a more skilled workforce and showcase their dedication to career growth, ultimately strengthening their talent pipeline and organisational resilience. To stay ahead, life sciences companies should invest in comprehensive training programmes to keep their workforce up-to-date with the latest industry developments. Larger companies have also made redundancies to streamline their operations in response to financial and strategic pressures.
.jpeg)
With public funding often constrained, many life sciences organizations are stepping into new roles as funders or collaborators in the broader health ecosystem. With patients frequently changing insurance plans, payers may be reluctant to invest in therapies with delayed savings. These treatments offer long-term or curative outcomes, but existing reimbursement models often do not account for their extended value. Some manufacturers are seeking to shift from point-of-sale discounts to rebate models, arguing that doing so would improve transparency and prevent misuse. Programs such as 340B and ongoing pharmacy benefit manager (PBM) reform efforts are driving manufacturers to reexamine pricing structures and rebate models. This shift marks a growing appreciation for the value compliance brings to cross-functional decision-making.
- Life sciences executives are focused on adapting, creating value, enhancing digital capabilities, and growing amid competitive pressure, business volatility, and changing customer needs.
- An omnichannel approach — one that seamlessly integrates digital platforms with more traditional models — will help ensure increased response and engagement.
- Some companies report responding to these external factors through familiar but practical levers such as cost and productivity programs, commercial strategy, investment prioritization, operating footprint decisions, and portfolio choices (figure 4).
- This may include innovative solutions such as genAI to improve the speed of risk assessment and documentation by streamlining new workflow processes for analyzing data and generating information required for FDA reporting.
.jpeg)
Over the years, we have designed and implemented a range of business process automations using NetSuite's SuiteFlow functionality, as well as custom scripts to automate processes that are unique to a specific business requirement. We work with our clients to develop custom user types across many different roles to ensure your team only has access to the information they need and that sensitive data can only be accessed with the right level of privilege in the system. Life sciences companies are required to report on various metrics, meaning a flexible and user-friendly report-writing solution is key. Program management software from Zanovoy can help you to better manage your product development process, track progress against milestones, and allocate resources effectively. We can help you to ensure that your software solutions are helping your team follow leading practices in compliance and product reporting.
Pricing changes under the Inflation Reduction Act (IRA) in the United States
Recent updates to these regulations have further complicated the recruitment process, making it even harder to find candidates with the necessary combination of technical skills and regulatory knowledge. The industry’s stringent regulatory environment requires professionals who are well-versed in global regulations, compliance standards, and quality control. As people live longer and birth rates decline, the demand for healthcare services and treatments is surging, adding pressure to an already strained talent pool. This gap in education is contributing to a growing shortage of qualified professionals with the necessary digital and data analysis capabilities. We will then look at key strategies executives can drive to overcome these issues and ensure a driven and highly skilled workforce to advance the future of the sector.
To add this to the challenge, executives now face shrinking talent pools, with more than 87,000 roles currently unfilled in the US alone. Despite a temporary boost during the COVID-19 pandemic driven by demand and investment, the life sciences industry, along with many other industries, has encountered a tougher environment. However, significant challenges remain in terms of data integration, cost, accessibility, and ensuring equitable challenges in life sciences industry care across diverse populations.